Evidence map›Paper›PMID 33750916›Full record

ArticleScientific reports2021

Tert-butylhydroquinone attenuates doxorubicin-induced dysregulation of testicular cytoprotective and steroidogenic genes, and improves spermatogenesis in rats.

Godwin Adakole Ujah, Victor Udo Nna, Joseph Bagi Suleiman, Chinedum Eleazu, Chukwuemeka Nwokocha, Joy Assima Rebene, Michael Umana Imowo, Emmanuel Ochui Obi, Charlette Amachree, Evarest Chigozie Udechukwu and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 38 citations in OpenAlex.

  1. Investigation of the Protective Effect ofInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Nrf2 signaling pathway and its molecular regulatory mechanism.Journal of Zhejiang University. Science. B · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The Role ofInternational journal of molecular sciences · 2023
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 3 countries.

Godwin Adakole UjahDepartment of Physiology, College of Medical Sciences, University of Calabar, P.M.B. 1115, Calabar, Cross River State, Nigeria.
Victor Udo NnaDepartment of Physiology, College of Medical Sciences, University of Calabar, P.M.B. 1115, Calabar, Cross River State, Nigeria. victorudon@unical.edu.ng.ORCID http://orcid.org/0000-0001-7616-9468
Joseph Bagi SuleimanDepartment of Physiology, School of Medical Sciences, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan, Malaysia.
Chinedum EleazuDepartment of Physiology, School of Medical Sciences, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan, Malaysia.
Chukwuemeka NwokochaDepartment of Basic Medical Sciences (Physiology Section), The University of the West Indies, Mona, Kingston 7, Jamaica.
Joy Assima RebeneDepartment of Physiology, College of Medical Sciences, University of Calabar, P.M.B. 1115, Calabar, Cross River State, Nigeria.
Michael Umana ImowoDepartment of Physiology, College of Medical Sciences, University of Calabar, P.M.B. 1115, Calabar, Cross River State, Nigeria.
Emmanuel Ochui ObiDepartment of Physiology, College of Medical Sciences, University of Calabar, P.M.B. 1115, Calabar, Cross River State, Nigeria.
Charlette AmachreeDepartment of Physiology, College of Medical Sciences, University of Calabar, P.M.B. 1115, Calabar, Cross River State, Nigeria.
Evarest Chigozie UdechukwuDepartment of Physiology, College of Medical Sciences, University of Calabar, P.M.B. 1115, Calabar, Cross River State, Nigeria.
Mahaneem MohamedDepartment of Physiology, School of Medical Sciences, Universiti Sains Malaysia, 16150, Kubang Kerian, Kelantan, Malaysia. mahaneem@usm.my.ORCID http://orcid.org/0000-0001-9333-1957
University of Calabar · NGUniversiti Sains Malaysia · MYUniversity of the West Indies System · JM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (DOX) is a broad-spectrum chemotherapeutic drug used in the treatment of cancers. It acts by generating reactive oxygen species in target cells. The actions are, however, not limited to cancerous cells as it attacks healthy cells, killing them. This study investigated the benefits of the antioxidant, tert-butylhydroquinone (tBHQ), on testicular toxicity following DOX therapy. Twenty-four adult male albino rats were assigned randomly into four groups (n = 6), namely: normal control (NC), tBHQ, DOX and tBHQ + DOX groups. tBHQ (50 mg/kg body weight in 1% DMSO) was administered orally for 14 consecutive days, while a single DOX dose (7 mg/kg body weight) was administered intraperitoneally on Day 8. DOX decreased sperm count, motility and viability, and decreased the levels of steroidogenesis-related proteins, and reproductive hormones. Furthermore, DOX decreased the expression of antioxidant cytoprotective genes, and decreased the protein level of proliferating cell nuclear antigen in the testis. Conversely, DOX increased the expression of pro-inflammatory and pro-apoptotic genes in the testis. These negative effects were ameliorated following the intervention with tBHQ. Our results suggest that tBHQ protects the testis and preserves both steroidogenesis and spermatogenesis in DOX-treated rats through the suppression of oxidative stress, inflammation and apoptosis.

Indexed as

AnimalsCytoprotectionDoxorubicinGene Expression RegulationHydroquinonesMaleRatsRats, WistarSpermatogenesisSperm MotilityTestis2-tert-butylhydroquinoneDoxorubicinHydroquinones

Identifiers

PMID33750916
PMCPMC7970903
OpenAlexW3135001193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.